AuraSense forms advisory board
This article was originally published in Scrip
AuraSense, a US biotechnology company founded in February 2009 to pursue the therapeutic potential of engineered nanoparticles, has formed an advisory board. The five members are: Mark Booth, chief commercial officer at Orexigen Therapeutics; Dr William O'Neill, executive dean for clinical affairs at Miller School of Medicine, University of Miami; Dr Bertram Pitt, professor of medicine emeritus, University of Michigan School of Medicine; Dr Steven Rosen, Genevieve Teuton professor of medicine, Feinberg School of Medicine, Northwestern University; and Dr Erik Sontheimer, associate professor, department of biochemistry, molecular biology and cell biology, Northwestern University.
You may also be interested in...
US-based law firm Morgan Lewis has appointed Donna Lee Yesner and Stephen Ruscus as partners in its Food and Drug Administration and healthcare practice, based in Washington, DC. Ms Yesner is the co-chair of the healthcare contracting committee of the ABA Public Contracts Section, while Mr Ruscus focuses his practice on public healthcare, government contracts and litigation.
Qforma, a provider of analytics and predictive modelling technologies for the health sciences industry, has elected Mark Spiers to its board of directors. Mr Spiers retired as president and CEO of Wolters Kluwer Pharma Solutions in April; he has also previously worked for Bristol-Myers Squibb, Pharmacia and MedPointe Pharmaceuticals.
The San Diego, California-based biopharmaceutical company Optimer Pharmaceuticals has appointed Dr Nancy Ruiz senior vice-president of R&D, Cynthia Schwalm senior vice-president of international and Dr Kasia Petchel senior vice-president of pharmacovigilance. These newly created positions will strengthen the company's management team as it prepares for the potential launch of its lead product candidate, Dificid (fidaxomicin). Dr Ruiz joins from Merck Research Laboratories (formerly Schering-Plough Research Institute), where she served as vice-president of project and pipeline management for infectious diseases. Ms. Schwalm was previously president of Eisai Pharmaceuticals, the US commercial arm of Tokyo-based Eisai Co, while Dr Petchel was formerly vice-president of global head drug safety risk management at Roche.